Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
about
Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization.Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patientsAntibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole bloodDetection of disseminated tumor cells in peripheral blood.Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.The measurement and therapeutic implications of circulating tumour cells in breast cancer.Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling.Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.The prognostic implications of circulating tumor cells in patients with breast cancer.Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical Analysis.Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer.Advances in genomic characterization of circulating tumor cells.Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: a preliminary study.Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.Detection of Disseminated Cancer Cells in Blood.Q57128658
P2860
Q24811648-64B60607-54A3-4DAE-A467-1BA31832B6B1Q30354652-C047AD6E-87F5-4508-A81F-8BDB33C7650AQ33797133-874F85B7-33DA-4157-9957-6A34EBF9F2EBQ35563888-9A689A5E-5C2D-4BD6-AF95-6E33804F8727Q36154564-B96E2567-8339-4043-963D-325B0FE9E2A2Q36272854-1AC6F412-45D4-408D-ABDA-E535E4600D2AQ36326722-B2412CA7-A98D-4EFE-B8AC-946DD6D49113Q36557784-5B3A18D1-48F6-4236-9995-1A758E25834BQ36955133-E896B7DA-EFBD-4A6C-8723-824B878770CCQ37079905-3F472CD3-F744-4C7D-9C96-414B4301D73AQ37398787-A833C813-A2F3-4812-932C-EFD876F94C1BQ37560932-AEBB91A3-301E-411C-B360-5FB3A982BF6DQ38215455-74105E53-F752-47FA-91A7-F9BDBE8E7D7FQ39293549-8F8DBBF1-C312-4801-9137-58A85857684CQ40093279-1B3C6957-7135-44F4-A5B5-EEA6FB9D4BF7Q47110040-A1C61BBA-14E3-4762-8354-A42A88E8FB9EQ50114923-FFB66AB0-C992-4046-BC7C-2CAA35124D90Q55333294-14A5DEF1-30F4-43CB-94B5-3AD76C0B15B3Q57128658-3EE18C22-CD31-4EEB-B306-9E58B44D1405
P2860
Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Multigene reverse transcriptio ...... ne-refractory prostate cancer.
@ast
Multigene reverse transcriptio ...... ne-refractory prostate cancer.
@en
type
label
Multigene reverse transcriptio ...... ne-refractory prostate cancer.
@ast
Multigene reverse transcriptio ...... ne-refractory prostate cancer.
@en
prefLabel
Multigene reverse transcriptio ...... ne-refractory prostate cancer.
@ast
Multigene reverse transcriptio ...... ne-refractory prostate cancer.
@en
P2093
P1433
P1476
Multigene reverse transcriptio ...... ne-refractory prostate cancer.
@en
P2093
Daniel R Zweitzig
Jose G Moreno
Leon W M M Terstappen
Leonard G Gomella
S Mark O'Hara
Steve Gross
P304
P356
10.1373/CLINCHEM.2003.028563
P407
P577
2004-02-26T00:00:00Z